HTGF et al. in Rigontec's €15m series-A extension

Boehringer Ingelheim Venture Fund, Forbion Capital Partners, NRW Bank, MP Healthcare Venture Management, Sunstone Capital and Wellington Partners Life Sciences also participated.

The funding will be used for the development of Rigontec's RIG-I agonist platform targeting oncological, anti-infective and inflammatory indications as well as supporting the progress of lead candidate RGT100 towards the clinical stages.

Previous funding
In April 2015, Forbion and Sunstone injected €4.8m into Rigontec, as part of the second closing of the company's series-A financing. It brought the total invested in the first funding round to €14.25m, following a €9.45m initial series-A in October 2014, which saw Wellington Partners and the Boehringer Ingelheim Venture Fund lead the round.

Company
Launched in January 2014 as a spinout from the Institute for Clinical Chemistry and Clinical Pharmacology at the University of Bonn, Rigontec develops ribonucleic-acid-based immunotherapeutics for the treatment of cancer and viral diseases.

The treatment works by mimicking a viral infection, inducing anti-tumour immunity. The Rigontec team comprises six people.

People
High-Tech Gründerfonds – Caroline Fichtner (investment director).
Rigontec – Christian Schetter (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Germany
• Venture